All In Biotech

Drug Trial Radar · NCT03395197

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,054 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,054

Actual

Start

Dec 18, 2017

Primary completion

Oct 3, 2022

Study completion Jun 30, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Astellas Pharma Inc
First posted
Jan 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.

Conditions

  • mCRPC

Interventions

  • Talazoparib with enzalutamideDrug

    Talazoparib 0.5 mg/day plus enzalutamide 160mg/day

  • Placebo with enzalutamideDrug

    Placebo plus enzalutamide 160 mg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Occuring Within the First 66 Days of Dosing - Part 1Time frame: Post dose on Day 1 up to Day 66 in Part 1
  2. Number of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by Preferred Term (PT) and Max CTCAE Grade Occuring Within the First 66 Days of Dosing - Part 1Time frame: Post dose on Day 1 up to Day 66 in Part 1
  3. Number of Participants With All-Causality TEAEs During the Overall Period of Part 1Time frame: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)
  4. Number of Participants With Treatment-Related TEAEs During the Overall Period of Part 1Time frame: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)
  5. Number of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by PT and Max CTCAE Grade Occuring Anytime After Dosing - Part 1Time frame: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)
  6. Number of Participants With Treatment-Related Clustered Treatment-Emergent Cytopenias by PT and Max CTCAE Grade in >=10% of Participants Occuring Anytime After Dosing - Part 1Time frame: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)
  7. Blinded Independent Central Review (BICR) Assessed Radiographic Progression-Free Survival (rPFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for All-Comers - Part 2 Cohort 1Time frame: From the start of treatment to the time of first documented progression, or death (maximum up to 42 months)
  8. BICR Assessed rPFS Per RECIST 1.1 in Patients With DDR Deficiencies - Part 2Time frame: From the start of treatment to the time of first documented progression, or death (maximum up to 38 months)

Locations

370 sites in 26 countries. Site status is shown where the registry gives one.

  • Alaska Urological Institute dba Alaska Clinical Research Center

    Anchorage, Alaska

  • Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers

    Chandler, Arizona

  • Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers

    Gilbert, Arizona

  • Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers

    Mesa, Arizona

  • Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers

    Mesa, Arizona

  • Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers

    Scottsdale, Arizona

  • Arizona Urology Specialists

    Tucson, Arizona

  • Arizona Urology Specialists

    Tucson, Arizona

  • Beverly Hills Cancer Center

    Beverly Hills, California

  • South County Hematology/Oncology

    Chula Vista, California

  • Sharp Rees-Stealy

    Chula Vista, California

  • Glendale Adventist Medical Center

    Glendale, California

  • Marin Cancer Care, Inc.

    Greenbrae, California

  • Cancer Center Oncology Medical Group

    La Mesa, California

  • Loma Linda University Cancer Center - Records Management Only

    Loma Linda, California

  • Loma Linda University Cancer Center - Hematology/Oncology Clinic

    Loma Linda, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • VA Long Beach Healthcare System

    Long Beach, California

  • UCLA Clark Urology Center

    Los Angeles, California

  • University of California, Irvine Medical Center

    Orange, California

  • Stanford Cancer Institute

    Palo Alto, California

  • Desert Hematology Oncology Medical Group, Incorporation

    Rancho Mirage, California

  • Eisenhower Medical Center

    Rancho Mirage, California

  • Medical Oncology Associates-SD

    San Diego, California

  • Sharp Memorial Hospital Investigational Pharmacy

    San Diego, California

  • Sharp Rees-Stealy

    San Diego, California

  • Stanford Health Care

    Stanford, California

  • University of Colorado Denver CTO/CTRC

    Aurora, Colorado

  • University of Colorado Hospital - Anschutz Cancer Pavilion

    Aurora, Colorado

  • University of Colorado Hospital- Anschutz Inpatient Pavilion

    Aurora, Colorado

  • University of Colorado Hospital- Anschutz Outpatient Pavilion

    Aurora, Colorado

  • University of Colorado Hospital

    Aurora, Colorado

  • The Urology Center of Colorado

    Denver, Colorado

  • Florida Cancer Specialists

    Altamonte Springs, Florida

  • Florida Cancer Specialists

    Brandon, Florida

  • Florida Cancer Specialists

    Clearwater, Florida

  • Florida Cancer Specialists

    Daytona Beach, Florida

  • Florida Cancer Specialists

    Fort Myers, Florida

  • Florida Cancer Specialists

    Gainesville, Florida

  • Lakeland Regional Health Hollis Cancer Center

    Lakeland, Florida

Showing 40 of 370 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.